Regeneron Pharmaceuticals (NQ:REGN)

732.11 -3.09 (-0.42%)

Delayed Quote Updated: 1:45 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

66 67 Next >

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

April 29, 2024

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and...

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study ↗

April 25, 2024

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.

Via Benzinga

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

April 25, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry ↗

April 18, 2024

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today ↗

April 17, 2024

Via Benzinga

Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views ↗

April 12, 2024

Via Benzinga

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

April 24, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Small-Cap Growth Stocks With Room To Run ↗

April 24, 2024

These two small-cap growth stocks could be ready to run.

Via The Motley Fool

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

April 22, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

April 18, 2024

From Kirby McInerney LLP

Via GlobeNewswire

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking ↗

April 11, 2024

Via Benzinga

Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends ↗

March 28, 2024

Via Benzinga

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm

April 17, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick ↗

April 17, 2024

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...

Via Benzinga

The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

April 17, 2024

From Law Offices of Frank R. Cruz

Via Business Wire

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals ↗

March 26, 2024

Via Benzinga

Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review ↗

April 12, 2024

The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.

Via Investor's Business Daily

Topics Economy

Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug ↗

April 11, 2024

The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated...

Via Benzinga

Topics Fraud

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

April 11, 2024

From Schall Law

Via GlobeNewswire

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity? ↗

April 11, 2024

Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise.

Via Investor's Business Daily

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

April 07, 2024

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Should You Sell This Stock Following a Regulatory Roadblock? ↗

April 05, 2024

It's not the first such obstacle this high-performing drugmaker has faced.

Via The Motley Fool

5 Healthcare Stocks to Buy for 2024 ↗

April 02, 2024

Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.

Via InvestorPlace

Topics Artificial Intelligence

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

April 01, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

April 01, 2024

Via Benzinga

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

Stock-Split Watch: Are These 2 Top Growth Stocks Next? ↗

March 28, 2024

Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.

Via The Motley Fool

3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗

March 26, 2024

These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.

Via InvestorPlace

FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns ↗

March 25, 2024

The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data...

Via Benzinga

Regeneron Provides Update on Biologics License Application for Odronextamab

March 25, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.